Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2019-01, Vol.33 (1), p.258-261
Hauptverfasser:	Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans J., Munder, Markus, Gerecke, Christian, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Hillengass, Jens, Raab, Marc S., Merz, Maximilian, Baertsch, Marc-Andrea, Jauch, Anna, Hose, Dirk, Martin, Hans, Lindemann, Hans-Walter, Blau, Igor W., Scheid, Christof, Weisel, Katja C., Goldschmidt, Hartmut
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/2779/109/1942 692/499 692/699/1541/1990/804 Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib Bortezomib - administration & dosage Brief Communication Cancer Research Critical Care Medicine Dexamethasone Dexamethasone - administration & dosage Female Follow-Up Studies Hematology Humans Induction therapy Inhibitor drugs Intensive Internal Medicine Male Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Oncology Prognosis Remission Induction Retrospective Studies Steroids Survival Rate Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!